Medinice S.A - Asset Resilience Ratio
Medinice S.A (ICE) has an Asset Resilience Ratio of 4.79% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ICE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Medinice S.A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medinice S.A balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Medinice S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Medinice S.A balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł1.69 Million | 4.79% |
| Total Liquid Assets | zł1.69 Million | 4.79% |
Asset Resilience Insights
- Limited Liquidity: Medinice S.A maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medinice S.A Industry Peers by Asset Resilience Ratio
Compare Medinice S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
|
Profound Medical Corp
TO:PRN |
Medical Devices | 67.66% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
Epitomee Medical Ltd
TA:EPIT |
Medical Devices | 0.24% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
Annual Asset Resilience Ratio for Medinice S.A (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Medinice S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.01% | zł3.00K ≈ $825.64 |
zł37.49 Million ≈ $10.32 Million |
-1.50pp |
| 2022-12-31 | 1.50% | zł630.00K ≈ $173.39K |
zł41.90 Million ≈ $11.53 Million |
+1.35pp |
| 2021-12-31 | 0.15% | zł75.00K ≈ $20.64K |
zł49.18 Million ≈ $13.53 Million |
+0.05pp |
| 2020-12-31 | 0.11% | zł22.00K ≈ $6.05K |
zł20.92 Million ≈ $5.76 Million |
-0.12pp |
| 2019-12-31 | 0.22% | zł25.95K ≈ $7.14K |
zł11.68 Million ≈ $3.22 Million |
+0.09pp |
| 2018-12-31 | 0.13% | zł10.00K ≈ $2.75K |
zł7.55 Million ≈ $2.08 Million |
+1.87pp |
| 2017-12-31 | -1.74% | zł-85.17K ≈ $-23.44K |
zł4.90 Million ≈ $1.35 Million |
-- |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more